As of June 30, 2024, Avalo had $93.4 million in cash and cash equivalents. Net cash used in operating activities was $22.5 million for the six months ended June 30, 2024, which includes a $7.5 million milestone payment to AlmataBio, Inc. pursuant to the acquisition in the first quarter. The Company’s current cash on hand is expected to fund operations into 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Welcomes New CMO with Competitive Package
- Avalo Therapeutics Announces Appointment of Dr. Mittie Doyle as Chief Medical Officer
- Avalo Therapeutics appoints Doyle as Chief Medical Officer
- Avalo Therapeutics announces active IND for AVTX-009